James W. Green Acquires 20,000 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. (NASDAQ:HBIOGet Free Report) CEO James W. Green acquired 20,000 shares of the stock in a transaction on Thursday, June 6th. The stock was bought at an average price of $3.07 per share, with a total value of $61,400.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,101,091 shares of the company’s stock, valued at $9,520,349.37. The purchase was disclosed in a filing with the SEC, which is available at this link.

Harvard Bioscience Stock Down 1.3 %

HBIO stock opened at $2.94 on Friday. The firm has a 50 day moving average price of $3.68 and a 200-day moving average price of $4.29. Harvard Bioscience, Inc. has a 52-week low of $2.92 and a 52-week high of $6.20. The company has a current ratio of 1.88, a quick ratio of 0.94 and a debt-to-equity ratio of 0.46.

Harvard Bioscience (NASDAQ:HBIOGet Free Report) last released its earnings results on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Harvard Bioscience had a negative net margin of 8.18% and a positive return on equity of 0.26%. The business had revenue of $28.15 million for the quarter, compared to analysts’ expectations of $27.80 million. As a group, research analysts forecast that Harvard Bioscience, Inc. will post 0.11 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, May 9th.

Check Out Our Latest Analysis on HBIO

Hedge Funds Weigh In On Harvard Bioscience

Several large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its holdings in shares of Harvard Bioscience by 1.2% during the third quarter. Bank of New York Mellon Corp now owns 227,002 shares of the medical instruments supplier’s stock valued at $976,000 after purchasing an additional 2,758 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Harvard Bioscience by 3.2% during the fourth quarter. New York State Common Retirement Fund now owns 142,460 shares of the medical instruments supplier’s stock valued at $762,000 after acquiring an additional 4,463 shares in the last quarter. Riverwater Partners LLC increased its position in shares of Harvard Bioscience by 14.1% during the first quarter. Riverwater Partners LLC now owns 93,197 shares of the medical instruments supplier’s stock valued at $395,000 after acquiring an additional 11,492 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Harvard Bioscience during the first quarter valued at approximately $54,000. Finally, Bailard Inc. bought a new stake in shares of Harvard Bioscience during the fourth quarter valued at approximately $106,000. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

About Harvard Bioscience

(Get Free Report)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.

Featured Articles

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.